In refractory anemia (RA) and refractory anemia with ringed sideroblasts (RARS) a discrepancy is observed between the decreased in vitro erythroid colony formation and the normal or increased number of normoblasts in the bone marrow. 
Introduction
Myelodysplasia (MDS) is a preleukemic disorder affecting the erythroid, myeloid and megakaryocytic lineage. The disorder is classified according the FAB classification and includes refractory anemia (RA) and refractory anemia with ringed sideroblasts (RARS). 1 In particular in RA and RARS a differentiation block is observed of the erythroid lineage. Several in vitro studies have shown that BFU-E and CFU-E do not expand in response to erythropoietin (Epo) or Epo plus mast cell growth factor (MGF). [2] [3] [4] [5] [6] [7] [8] Moreover a differentiation block is observed at the level of early erythroid progenitor cell which is frequently associated with the aberrant expression of Evi-1. 9 The Evi-1 gene encodes a zinc finger protein that functions as transcription factor. It is suggested that Evi-1 blocks cellular differentiation by binding to GATA-1 or other specific DNA sequences controlling gene expression. 10, 11 Despite the limited in vitro proliferative capacity of the erythroid clonogenic
Correspondence: E Vellenga, Department of Hematology, University Hospital, PO Box 30.001, 9700 RB Groningen, The Netherlands; Fax: 31 50 3614862 Received 9 July 1997; accepted 2 December 1997 cell, a normal or increased number of normoblasts are observed in the bone marrow suggesting that in vivo the differentiation pathway is not totally blocked. In view of these findings it will be of interest to compare the in vitro and in vivo behavior of erythroid precursor cells. Ferrokinetic studies can be used to study the in vivo proliferation of erythroid progenitors by measuring the erythron transferrin uptake (ETU). [12] [13] [14] In addition the soluble transferrin receptor (sTfR) can be used to study the proliferative capacity of the erythroid lineage in vivo. Previous studies have demonstrated that soluble transferrin receptor measurement reflects the degree of erythropoiesis. [15] [16] [17] To study the relevance of the in vivo and in vitro parameters in MDS, 24 RA and five RARS patients were studied with regard to clinical behavior, in vitro erythroid colony formation, ferrokinetic measurement and sTfR.
Materials and methods
Bone marrow cells were obtained after informed consent from 29 patients with MDS. The patients were classified according FAB criteria as RA (n = 24) and RARS (n = 5). Affected cell lineages were scored according to the Bournemouth scoring system 18 (bone marrow blasts Ͼ5%, Hb Ͻ6.3 mmol/l, platelet count Ͻ100 × 10 9 /l and neutrophil count Ͻ2.5 × 10 9 /l). The total bone marrow hematopoietic cellularity vs fat spaces was examined on bone marrow specimens in 23 cases (21 RA, two RARS). 19 Ferrokinetic studies 12, 13 After incubation of 370-550 kBq 59 Fe-citrate with donor plasma for 30 min at 37°C, 59 Fe not bound to transferrin, was removed by passing the mixture through an anion exchange resin column. After passing through a sterile 0.22 m millipore filter the eluate was drawn into a 10 ml syringe.
Blood samples were taken at regular intervals of 10, 20, 30, 60, 90 and 120 min after injection of the patients with radiolabelled iron. Plasma iron disappearance rate was determined for all points from the plasma radio-activity by the least-squares method. The plasma iron turnover (PIT) was calculated according the following formula:
Transferrin iron uptake (TIU) and erythron transferrin uptake (ETU) were calculated using the following formula: 
Cytogenetic examination
Bone marrow cells were cultured for 24 and 48 h in RPMI-1640 (Life Technologies, Breda, The Netherlands) supplemented with 15% FCS (Bodinco, Alkmaar, The Netherlands), glutamine and antibiotics (Life Technologies). The cultures were harvested and chromosome preparations were made according to standard cytogenetic techniques. The chromosomes were G-banded using trypsin (Difco, Detroit, MI, USA) or pancreatin (Sigma) and karyotypes described according to the ISCN 95 guidelines for Cancer Cytogenetics. 22 
Soluble transferrin receptor
Microtiter strips coated with anti-sTfR (Ramco Laboratories, Houston, TX, USA) are incubated with patient blood samples. After washing a second monoclonal anti-sTfR-antibody conjugated to horseradish peroxidase (Ramco Laboratories) is incubated. Following a second washing the formed complex is detected using a tetramethylbenzidin/peroxide substrate. Samples are read at 450 nm in the MRX Revelation (Dynex Technologies, Denkendorf, Germany).
Erythropoietin
Serum epo levels were determined with the epo-radioimmunoassay (Incstar, Stillwater, OK, USA). Normal values are 10-30 IU/l.
Figure 1
Relation of soluble transferrin receptor (sTfR in g/ml) and ETU in mol/l blood/day in RA (n = 13, P Ͻ 0.05, r = 0.64) and RARS. b, RA, ć, RARS.
Figure 2
Relation of serum epo levels (IU/l, n = 25) with hematocrit (ć) in % (P Ͻ 0.05, r = 0.69), and with percentage of erythropoiesis (í) in bone marrow specimens (normal 13-34%, P Ͻ 0.05, r = 0.51).
Figure 3
Relation between observed erythropoietin levels and erythropoietin levels derived from the hematocrit according to the formula: log(epo) = 4.746 − (0.093-hct (%)) with 95% CI. 42 +, serum epo; ć, calculated epo.
Statistical analysis
Linear regression analysis was used for Figures 1, 2 and 3 by Graphpad Prism version 1.03 (Graphpad Software, San Diego, CA, USA). Statistical analysis of differences between RA and RARS and transfusion dependency were performed by the independent samples t-test by SPSS, release 6.0 (SPSS, Chicago, IL, USA). Results with P Ͻ 0.05 were considered significant.
Results

Patient characteristics
Twenty-nine patients with MDS were included in the study. Mean age was 61 years (range . In all cases the erythroid lineage was involved. In 12 cases (41%) different cell lineages were affected according to the Bournemouth scoring system (Table 1 ). Bone marrow examination at time of diagnosis demonstrated a great variability in the percentage of normoblasts. In 14% of the cases a decreased percentage of erythropoiesis was observed, ie Ͻ13% normoblasts (normal 13-34%, 23, 24 mean, 10%, range 7-13%); in 34% of the cases a normal percentage of erythropoiesis was observed (13-34% normoblasts, mean, 26%, range 15-33%), whereas in 52% of the cases an increased percentage of erythropoiesis was found (Ͼ34% normoblasts, mean, 45%, range 35-60%). Between RA and RARS no significant difference could be established (P = 0.99). When the percentage of erythropoiesis was corrected for overall marrow cellularity by multiplying the overall bone marrow cellularity with the percentage of erythropoiesis, no significant difference (P = 0.44) could be observed. Cytogenetic examination of bone marrow samples was performed in 76% of the patients. In nine patients cytogenetic abnormalities were observed including trisomy chromosome 8 (n = 4), partial or total deletion of the long arm of chromosome 7 (n = 4), deletion of the long arm of chromosome 5 (n = 3) and deletion of the Y chromosome (n = 2) (see Table 2 ). 
Soluble transferrin receptor
In 13 cases with RA sTfR levels were measured. The sTfR levels showed a distinct relationship with the ETU values in cases with RA (P Ͻ 0.05, r = 0.64, Figure 1 ). In contrast, in RARS higher ETU values were found with the corresponding sTfR levels in comparison to RA. The limited data however do not permit statistical analysis.
Serum erythropoietin levels
Serum epo levels were measured in 25 of the cases with RA and RARS. 72% of the cases had an appropriate epo response to the degree of anemia. Epo response was calculated by the formula described by Cazzola and Beguin ( Figure 3) . 42 In cases who were transfusion-dependent epo levels were higher compared to the cases who were transfusion-independent (102.8 ± 77.23 vs 84.5 ± 103.12, Table 3 ). A significant inverse correlation was found between the serum epo levels, hematocrit and the percentage of erythropoiesis in bone marrow (Figure 2 ). However no relation existed between serum epo levels and ETU (P = 0.66) or serum epo levels and sTfR (P = 0.50). The serum epo levels in the transfusion-dependent group were determined at least 14 days after the latest blood transfusion.
Transfusion dependency
Finally, we analyzed whether the studied parameters correlated with transfusion dependency or independency. 59% of the patients were red blood cell transfusion-dependent (17/29). All patients with a decreased percentage of erythropoiesis in the bone marrow required regular transfusions (P Ͻ 0.05), while 50% of the cases with a normal and 47% of the patients with an increased percentage of erythropoiesis received regular transfusions (NS). Transfusions had to be administered more frequently in cases with normal or increased ETU values compared to the group with diminished ETU values (75% vs 17%, P Ͻ 0.05). Moreover it appeared that in cases with more than 10 BFU-E/10 4 CD34 + cells transfusion dependency was less pronounced compared to the cases with no colony formation (33 vs 67%, P = 0.32). Finally Table 3 Characteristics of the transfusion-independent and -dependent group in refractory anemia and refractory anemia with ringed sideroblasts it was shown that cases with cytogenetic abnormalities were significantly more transfusion-dependent (P Ͻ 0.05, Table 3 ).
Discussion
In MDS, anemia is usually the presenting symptom, whereby transfusion of red blood cells is frequently needed, in spite of the hyperplasia of the erythroid lineage in bone marrow. The cause of this ineffective erythropoiesis is not well defined. Several in vitro studies have shown that erythroid progenitors in vitro do not expand in response to epo or epo plus MGF stimulation. [2] [3] [4] [5] [6] [7] [8] Also the in vivo treatment of MDS patients with rhEPO is of limited benefit. [25] [26] [27] However, in spite of the limited in vitro proliferative capacity of the erythroid progenitor cell, a normal or increased number of normoblasts are observed in the bone marrow suggesting that in vivo the differentiation pathway is not totally blocked. These findings prompted us to compare the in vivo and in vitro behavior of erythroid precursor cells in MDS. Ferrokinetic studies can be used to determine the proliferative status of erythroid progenitors in vivo by measuring the ETU. [12] [13] [14] In addition, the soluble transferrin receptor (sTfR) can be used to study the proliferative capacity of the erythroid lineage in vivo. [15] [16] [17] Decreased sTfR levels are observed in patients with erythroid hypoplasia as a result of aplastic anemia, chronic renal failure or after intensive chemotherapy. Increased levels are detected in cases with erythroid hyperplasia due to hemolytic anemia and thalassemia. Moreover it has been demonstrated that sTfR correlates with plasma iron turnover. 28 The present study demonstrates that in RA a normal or increased ETU correlates with the sTfR level and with an increased percentage of erythroblasts in the bone marrow. When corrected for overall bone marrow cellularity similar results were obtained. In contrast, in vitro studies did not confirm the high proliferative status of erythroid progenitors and demonstrated an impaired in vitro erythroid colony formation. This might suggest that the proliferative and differentiative capacity of erythroid precursors are uncoupled. This is supported by a recent study demonstrating that CD34 + -sorted bone marrow cells of RA patients demonstrated limited proliferative response to epo plus MGF stimulation, but retained the capacity to differentiate. 29 Alternatively, the used in vitro culture assay is not adequate for MDS erythroid progenitors in providing an adequate proliferative signal, resulting in an enhanced tendency for apoptosis. 30, 31 This notion is also supported by ferrokinetic studies demonstrating normal or enhanced ETU values reflecting the proliferative status of erythroid progenitors at the level of erythroblasts. It is also conceivable that a defect is localized at the level of erythroblastic denucleation. An impaired denucleation might also imply an accumulation of erythroblasts in the bone marrow.
In a subgroup of RA patients, low ETU values were observed which was associated with transfusion independency. In addition higher BFU-E values were observed in this group suggesting that the erythroid progenitor cell is less affected. These might be the characteristics of the group that are sensitive for the in vivo effects of epo, eg transfusion independency and low epo serum levels. 26, 27 In RARS, ETU values are significantly increased in all cases. The high ETU values might be related to a disturbed handling and sequestering of Fe at the mitochondrial level in the sideroblasts. 32 This might explain that in contrast to RA no correlation is observed with sTfR. The data suggest that sTfR is a more sensitive assay in this subcategory of MDS patients to measure the erythroid proliferative capacity in vivo.
The stimulation for epo release is generally assumed to be diminished oxygen delivery to peritubular epo-producing cells. This can be evoked by hypoxia or anemia. [33] [34] [35] Interestingly, increased serum epo levels decline after 48 h following the occurrence of anemia and return to normal levels within a week, despite the continued presence of anemia. 36, 37 Persistent anemia, however, due to iron deficiency, vitamin B12 deficiency or aplastic anemia is associated with the continued presence of increased epo levels. Immediately upon start of iron/vitamin B12 administration or after recovery from aplastic anemia epo levels fall before any increase in blood hemoglobin concentration has been noticed. [38] [39] [40] [41] The finding in this study that epo levels are inversely correlated with the percentage of erythropoiesis in the bone marrow suggests that epo synthesis is not only correlated to the degree of anemia or hypoxia but might also be reflected by the proliferative status of the erythroid precursor.
In summary, these data demonstrate that different patterns of defects in the erythropoiesis can be observed in RA and RARS whereby normal to increased ETU levels and the presence of cytogenetic abnormalities differentiates between cases of RA with ineffective erythropoiesis associated with regular transfusions and cases which are relatively transfusion-independent in time. The in vitro colony formation and erythroid bone marrow cellularity are insensitive to differentiate between these two groups.
